BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...
Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform...
BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...
BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...
BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...
New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy Special editorial highlights the...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0482 | -9.6111665005 | 0.5015 | 0.5015 | 0.38 | 84446 | 0.43113162 | CS |
4 | -0.2259 | -33.2597173145 | 0.6792 | 0.7208 | 0.38 | 198422 | 0.59193923 | CS |
12 | 0.0463 | 11.3759213759 | 0.407 | 0.8655 | 0.28 | 423060 | 0.56331302 | CS |
26 | -2.4667 | -84.4760273973 | 2.92 | 2.99 | 0.185 | 476797 | 0.47554831 | CS |
52 | -2.5067 | -84.6858108108 | 2.96 | 3.16 | 0.185 | 466132 | 0.47730788 | CS |
156 | -2.5067 | -84.6858108108 | 2.96 | 3.16 | 0.185 | 466132 | 0.47730788 | CS |
260 | -2.5067 | -84.6858108108 | 2.96 | 3.16 | 0.185 | 466132 | 0.47730788 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관